恩替卡韦和替诺福韦地索普西富马酸盐治疗初治和经验丰富

StephenW

Saudi J Gastroenterol. 2018 Jul 6. doi: 10.4103/sjg.SJG_49_18. [Epub ahead of print]
Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM1, Shin HP2, Lee JI2, Joo KR2, Cha JM2, Jeon JW2, Yoon JY2, Kwak MS2.
Author information

1
    Department of Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
2
    Department of Gastroenterology and Hepatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

Abstract
Background/Aim:

The goal of antiviral therapy for chronic hepatitis B (CHB) is to improve survival of the patients by achieving a complete virological response (CVR). This study aimed to evaluate long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in nucleos(t)ide analog (NA)-naïve and NA-experienced Korean patients with CHB and to determine the incidence of cirrhosis-related complications in these patients.
Patients and Methods:

We retrospectively reviewed medical records of all patients treated with ETV or TDF from July 2007 to January 2017. We examined CVR and analyzed the predictive factors influencing the rate of CVR and evaluated the incidences of cirrhosis-related complications.
Results:

The proportion of patients who achieved CVR was 94.2% in the ETV group and 91.1% in the TDF group (P = 0.358). Among patients who achieved CVR, the mean time to CVR was 13.5 ± 14.3 months in the ETV group and 11.5 ± 10.6 months in the TDF group (P = 0.169). Positive predictive factors for CVR included the current treatment with TDF, a low hepatitis B virus DNA level, negative hepatitis B e-antigen status, and high alanine aminotransferase level in baseline laboratory test. The annual incidence rate of HCC was 127 per 10,000 patient-years (1.27% per year) in ETV group, and 85 per 10,000 patient-years (0.85% per year) in TDF group (P = 0.526).
Conclusion:

Both ETV and TDF therapy resulted in a high CVR, and the annual incidence rates of HCC and other cirrhosis-related complications were not significantly different between the two treatment groups.
KEYWORDS:

Complete virological response; efficacy; entecavir; hepatitis B; tenofovir

PMID:
    30004042

StephenW

Saudi J Gastroenterol。 2018年7月6日doi：10.4103 / sjg.SJG_49_18。 [提前打印]
恩替卡韦和替诺福韦地索普西富马酸盐治疗初治和经验丰富的慢性乙型肝炎患者的真实世界单中心体验
Kim YM1，Shin HP2，Lee JI2，Joo KR2，Cha JM2，Jeon JW2，Yoon JY2，Kwak MS2。
作者信息

1
    韩国首尔庆熙大学研究生院医学系。
2
    韩国首尔庆熙大学医学院江东庆熙大学医院消化内科和肝病学系。

抽象
背景/目的：

慢性乙型肝炎（CHB）抗病毒治疗的目标是通过实现完整的病毒学应答（CVR）来改善患者的存活率。这项研究旨在评估恩替卡韦（ETV）和替诺福韦地索普西富马酸盐（TDF）在核苷（酸）类似物（NA）-naïve和NA经验的韩国CHB患者中的长期疗效，并确定肝硬化相关的发病率这些患者的并发症。
患者和方法：

我们回顾性地回顾了2007年7月至2017年1月期间接受ETV或TDF治疗的所有患者的医疗记录。我们检查了CVR并分析了影响CVR率的预测因素，并评估了肝硬化相关并发症的发生率。
结果：

达到CVR的患者比例在ETV组为94.2％，在TDF组为91.1％（P = 0.358）。在达到CVR的患者中，ETV组的平均CVR时间为13.5±14.3个月，TDF组为11.5±10.6个月（P = 0.169）。 CVR的阳性预测因子包括目前用TDF治疗，低乙型肝炎病毒DNA水平，乙型肝炎e抗原阳性状态和基线实验室检测中高丙氨酸氨基转移酶水平。在ETV组，HCC的年发病率为每10,000患者年127例（每年1.27％），TDF组为每10,000患者年85例（每年0.85％）（P = 0.526）。
结论：

ETV和TDF治疗均导致高CVR，HCC和其他肝硬化相关并发症的年发病率在两个治疗组之间无显着差异。
关键词：

完整的病毒学反应;功效;恩替卡韦;乙型肝炎;替诺福韦

结论：
    30004042